SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the Company will present the results from the ongoing LGD-6972 Phase 1b Multiple-Ascending Dose trial in a poster presentation at the American Diabetes Association 75th Scientific Sessions on Sunday, June 7th, at the Boston Convention and Exhibition Center.
Help employers find you! Check out all the jobs and post your resume.
